Related Experiment Video
Updated: Aug 6, 2026

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
Published on: August 30, 2011
Anorexigen-related cardiopulmonary toxicity
1University of California, Los Angeles, Schools of Medicine and Nursing and Cedars-Sinai Medical Center, Los Angeles, USA.
Abstract:
Three years after the withdrawal of fenfluramine and dexfenfluramine from the market, the magnitude and prevalence of their deleterious cardiopulmonary effects remain undetermined. The links between these anorexigens and valvular heart disease and primary pulmonary hypertension, however, are clearly established. Because some evidence indicates that the valvular lesions may regress with cessation of the drug, management guidelines are still in flux. Patient reassurance and close surveillance, including serial echocardiography in selected cases, are warranted.
Insights
Fenfluramine and dexfenfluramine, anorexigens, are linked to valvular heart disease and pulmonary hypertension. Their long-term cardiopulmonary effects and regression potential require ongoing patient surveillance and updated management guidelines.
Area of Science:
- Cardiology
- Pharmacology
- Pulmonology
Background:
- Fenfluramine and dexfenfluramine were withdrawn from the market due to concerns about adverse cardiopulmonary effects.
- Established links exist between these anorexigens and the development of valvular heart disease and primary pulmonary hypertension.
- The precise magnitude and prevalence of these deleterious effects remain undetermined years after market withdrawal.
Purpose of the Study:
- To assess the undetermined cardiopulmonary effects of fenfluramine and dexfenfluramine.
- To review the established links to valvular heart disease and primary pulmonary hypertension.
- To inform evolving management guidelines considering potential regression of valvular lesions.
Main Methods:
- Review of existing evidence on fenfluramine and dexfenfluramine.
- Analysis of established links to valvular heart disease and primary pulmonary hypertension.
- Consideration of data suggesting potential regression of drug-induced valvular lesions.
Main Results:
- The full extent and prevalence of cardiopulmonary damage from fenfluramine and dexfenfluramine are still not fully quantified.
- A clear association between these drugs and valvular heart disease and primary pulmonary hypertension is established.
- Emerging evidence suggests that valvular lesions may regress after drug cessation.
Conclusions:
- Despite market withdrawal, the long-term impact of fenfluramine and dexfenfluramine necessitates continued vigilance.
- Management strategies must adapt to the possibility of lesion regression.
- Close patient monitoring, including echocardiography, is recommended for affected individuals.
Related Concept Videos
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III
Drug Toxicity: Overview
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions
Drug Toxicity: Allergic Reactions

